Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes

(2018) Vijaya L. Damaraju et al.   BIOCHEMICAL PHARMACOLOGY

Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism

(2017) Neeltje A E Allard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment

(2015) Meri Kekale et al.   Patient Preference and Adherence

Imatinib Activates Pathological Hypertrophy by Altering Myocyte Calcium Regulation

(2014) Larry A. Barr et al.   CTS-Clinical and Translational Science

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

(2013) F Efficace et al.   LEUKEMIA

Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib

(2012) Giovanni Caocci et al.   LEUKEMIA RESEARCH

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES